Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.¹⁾ Coronaviruses cause respiratory tract infections in humans, with most severe cases triggered by SARS, MERS, and, recently, COVID-19 (while the disease is named COVID-19, the virus that causes it was named SARS-CoV-2).²⁾ The lungs are the organs most affected by COVID-19 because the virus (using a special surface glycoprotein) accesses host cells via the enzyme ACE2, which is most abundant in the type II alveolar cells of the lungs.³⁾ Some of the trends in anti-SARS-CoV-2 agent development include the search for the viral proteases 3CLpro or PLpro inhibitors, viral protein expression inhibitors, viral entry to host cells inhibitors, as well as inhibitors of viral replication.⁴⁾ TCI offers many antiviral agents useful for research and experiment. Currently reported mechanisms and target virus types are summarized below. Literature information is also provided on the "Application" tab in the product details page viewable from the link of Product Number.

Page Top

Related Products

• Chloroquine Diphosphate (Product Number：C2301)
• Hydroxychloroquine Sulfate (Product Number：H1306)
• Camostat Mesylate (Product Number：C2977)
• Gabexate Mesylate (Product Number：G0464)
• Nafamostat Mesylate (Product Number：N0959)
• Dipyridamole (Product Number：D2274)
• Ciclesonide (Product Number：C3701)
• Dexamethasone (Product Number：D1961)
• Cepharanthine (Product Number：M2968)

Page Top

Related Product Category Pages

• Protease Inhibitors [Enzyme Inhibitors]
• Macrolide Antibiotics (for Research and Experimental Use)
• Antiparasitic Ingredients, Antiprotozoal Ingredients, Antihelminthic Ingredients (for Research and Experimental Use)
• Steroidal Anti-Inflammatories (for Research and Experimental Use)
• Antiplatelet Agents (for Research and Experimental Use)

Page Top

Product Brochures

Page Top

References

• 1) Coronaviruses: An Overview of Their Replication and Pathogenesis
  • A. R. Fehr, S. Perlman, in Coronaviruses Methods and Protocols, ed. by H. J. Maier, E. Bickerton, P. Britton, Humana Press, New York, 2015, pp. 1-23.
• 2) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  • A. E. Gorbalenya, S. C. Baker, R. S. Baric, R. J. de Groot, C. Drosten, A. A. Gulyaeva, B. L. Haagmans, C. Lauber, A. M. Leontovich, B. W. Neuman, D. Penzar, S. Perlman, L. L. M. Poon, D. V. Samborskiy, I. A. Sidorov, I. Sola, J. Ziebuhr, Nat. Microbiol. 2020.
• 3) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
  • M. Letko, A. Marzi, V. Munster, Nat. Microbiol. 2020.
• 4) Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
  • C. Liu, Q. Zhou, Y. Li, L. V. Garner, S. P. Watkins, L. J. Carter, J. Smoot, A. C. Gregg, A. D. Daniels, S. Jervey, D. Albaiu, ACS Cent. Sci. 2020.
• 5) Current Status of Drug development against the Novel Coronavirus, SARS-CoV-2 -Evaluation of therapeutic agents based on scientific evidence-
  • M. Ujike, in TCIMAIL, No.184, 2020, pp.2-14.

Page Top